Could Proteostasis Therapeutics Inc (NASDAQ:PTI) Go Down After Its Newest Short Interest Report?

April 13, 2018 - By Marguerite Chambers

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Logo

The stock of Proteostasis Therapeutics Inc (NASDAQ:PTI) registered a decrease of 3.62% in short interest. PTI’s total short interest was 948,800 shares in April as published by FINRA. Its down 3.62% from 984,400 shares, reported previously. With 629,000 shares average volume, it will take short sellers 2 days to cover their PTI’s short positions. The short interest to Proteostasis Therapeutics Inc’s float is 6.54%.

The stock decreased 2.82% or $0.1461 during the last trading session, reaching $5.0439. About 372,589 shares traded. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 55.82% since April 13, 2017 and is downtrending. It has underperformed by 67.37% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $173.93 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.